文献速递区域麻醉与超声疼痛医学

Medicare人群硬膜外皮质类固醇注射严重脊柱不良事件风险

Risk of serious spinal adverse events associated with epidural corticosteroid injections in the Medicare population.
PubMed 文献 · Reg Anesth Pain Med · 2020-12-04

BACKGROUND: Epidural corticosteroid injections (ESIs) are widely performed and have an unquantified risk of serious spinal adverse events (SSAEs).…

要点

  • 颈/胸段注射严重脊柱不良事件风险显著高于腰/骶段注射。
  • 颗粒型与非颗粒型皮质类固醇制剂的事件发生率未见显著差异。

核心结论

  • 2009至2015年Medicare人群中硬膜外皮质类固醇注射后严重脊柱不良事件发生率低。
  • 颈/胸段硬膜外注射的严重脊柱不良事件风险显著高于腰/骶段注射。
  • 不同皮质类固醇制剂(颗粒型与非颗粒型)的事件发生率相似。

研究设计与样本

  • 纳入2009年1月1日至2015年9月30日期间接受硬膜外皮质类固醇注射的Medicare A/B部分参保患者。
  • 对首次合格注射后3天内出现脊柱相关诊断的潜在病例进行病历复核,分类为probable、possible或非病例。

临床怎么用

  • 临床行硬膜外皮质类固醇注射时应知晓严重脊柱不良事件虽罕见但确实存在。
  • 颈/胸段硬膜外皮质类固醇注射的严重脊柱不良事件风险高于腰/骶段,决策时需权衡。
  • 颗粒型与非颗粒型皮质类固醇制剂在严重脊柱不良事件风险上未见显著差异。

局限性

  • 仅43例潜在病例接受病历复核,事件分类可能存在漏判或错分。
  • 研究基于Medicare参保人群,结果外推至其他人群需谨慎。
  • 观察性设计无法排除混杂因素对节段和制剂比较的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidural corticosteroid injections (ESIs) are widely performed and have an unquantified risk of serious spinal adverse events (SSAEs). We sought to determine the rate of SSAEs following ESI and to compare the rates by spinal level, injection approach and corticosteroid formulation. METHODS: We included patients enrolled in Medicare parts A and B who had an ESI between 1 January 2009 and 30 September 2015. We identified potential cases as patients with spine-related diagnoses within 3 days after the first eligible ESI. Event categorization as probable, possible or non-case was based on review of medical records. The rates of probable and possible cases were expressed per 1 000 000 patients overall, and by spinal level, injection approach and corticosteroid formulation. A score test was used to compare these rates. RESULTS: We identified 1 355 957 eligible ESIs during the study period. Of the 110 potential cases, 43 were selected for medical record review and 11 were categorized as probable, yielding a rate of 8.1 per 1 000 000 patients (95% CI 4.5 to 14.5). Risk of SSAEs was statistically higher with cervical/thoracic injections (29.4, 95% CI 12.5 to 68.8) compared with lumbar/sacral injections (5.1, 95% CI 2.3 to 11.0) (p value 0.001). Event rates for lumbar/sacral non-transforaminal injections was 8.8 (95% CI 4.0 to 19.1). Event rates for particulate (7.5, 95% CI 3.9 to 14.2) and non-particulate formulations (13.1, 95% CI 3.6 to 47.9) appeared similar (p value 0.47). CONCLUSION: Between 2009 and 2015, rates of SSAEs following ESI in the Medicare population were low. Patients receiving cervical/thoracic ESIs were at higher risk of SSAE than those receiving lumbar/sacral ESIs. Event rates were similar for each corticosteroid formulation.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Eworuke E, Crisafi L, Liao J, et al. Risk of serious spinal adverse events associated with epidural corticosteroid injections in the Medicare population. Reg Anesth Pain Med. 2020. PMID: 33277405. doi:10.1136/rapm-2020-101778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。